Back to the main directory
EarningsReview / Equity
- Straumann Holding - STRONG START TO THE YEAR AND LOW TARIFFS RISK by Equita Sim
- Q1’25 First take: organic growth slightly ahead, driven by pricing by BNP Paribas Exane
- Q1'25 First Take: +21% EBIT beat ; FY25 Guidance confirmed by BNP Paribas Exane
- Hangzhou Oxygen Plant (002430 CH) by HSBC
- Hipay - CA T1 2025 by MidCap Partners
- 吉比特（603444 CH） by HSBC
- 1Q25 EBIT beat and FY25 guidance confirmed by BNP Paribas Exane
- Q1'25 results: execution surprisingly solid, weak onshore orders by BNP Paribas Exane
- Hipay - Q1 revenue by MidCap Partners
- INVEST SECURITIES - OSE IMMUNO : + de 90% de répondeurs en phase de maintenance ! - ACHAT, OC 14,7€ by Invest Securities
- 1Q25 sales/Net Income adj. 1%/11% above cons, flat US volumes, FY25 guide confirmed by BNP Paribas Exane
- 1Q25 sales/adj. EBITA 2%/15% above. Tariffs drive 100bps cut to FY25 adj. EBITA margin guide by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Good operating figures but still weak FCF by BNP Paribas Exane
- Cognex Corp (CGNX US) by HSBC
- 石头科技（688169 CH） by HSBC
- Hipay - CA T1 2025 by UBS AG
- Elis - En ligne avec les attentes by UBS AG
- G-bits (603444 CH) by UBS AG
- Elis - In line with expectations by UBS AG
- CRH; 1Q25 3% ahead, Guide unch, Growth Investments Continue by UBS AG
- NAV falls 3.2p/sh (2.8%) during 1Q on weather/macro factors by UBS AG
- INDRA: 1Q25 results (=/-) by UBS AG
- Morning Notes - May 6 2025 (AEDb BB, BPOST BB, GBLB BB, PNL NA) by UBS AG
- Schibsted (Sell, TP: NOK280.00) - Prisjakt sold at low price by UBS AG
- Q125 revenue & EBITDA beat, strong KPIs, guidance reiterated -positive by BNP Paribas Exane
- Q1 25 - first take: EBIT a slight miss; guidance confirmed by BNP Paribas Exane
- 1Q results below consensus, still no guidance by BNP Paribas Exane
- 杭氧股份（002430 CH） by HSBC
- Elis - En ligne avec les attentes by MidCap Partners
- G-bits (603444 CH) by HSBC
- INVEST SECURITIES - BIGBEN : Rien d'annoncé au sujet du refinancement - ACHAT, OC 1,9€ vs 2,4€ by Invest Securities
- Elis - In line with expectations by MidCap Partners
- INVEST SECURITIES - NACON : Fin d'année anecdotique, l'exercice 2025/26 sera clé - ACHAT, OC 1,5€ vs 1,6€ by Invest Securities
- NAV falls 3.2p/sh (2.8%) during 1Q on weather/macro factors by BNP Paribas Exane
- Avanza / Nordnet April KPIs by BNP Paribas Exane
- Prosegur - Increasing TP by 11% on growth across lines; Buy by JB Capital Markets
- FAD Feedback: Multiple revenue prongs to drive $1bn in 2026 AI revs by BNP Paribas Exane
- FCX, AAL, SZG, ACX, CLF, SSAB, APAM, STEEL US, STRATEGY by BNP Paribas Exane
- CSC Financial (601066 CH/6066 HK) by HSBC
- Roborock (688169 CH) by HSBC
- 1Q25 EBIT beat and FY25 guidance confirmed by UBS AG
- 吉比特（603444 CH） by UBS AG
- Hipay - Q1 revenue by UBS AG
- Q1'25 results: execution surprisingly solid, weak onshore orders by UBS AG
- Diageo; Q3’25 preview: Guinness is Good for Diageo ahead of Dublin event - (Hold) by UBS AG
- 1Q25 sales/Net Income adj. 1%/11% above cons, flat US volumes, FY25 guide confirmed by UBS AG
- 1Q25 sales/adj. EBITA 2%/15% above. Tariffs drive 100bps cut to FY25 adj. EBITA margin guide by UBS AG
- Avanza / Nordnet April KPIs by UBS AG
- Q1'25 conf call: cautious near-term commentary outweighs Q1 performance by BNP Paribas Exane